What are the Historical Developments and Current Growth Metrics of the Neutropenia Biologic Drug Treatment Market?
The neutropenia biologic drug treatment market has seen considerable growth due to a variety of factors.
• The market size of biologic drugs for treating neutropenia has seen robust growth in the past few years. It is projected to further expand from $13.22 billion in 2024 to $14.08 billion in 2025, displaying a compound annual growth rate (CAGR) of 6.5%.
The expansion in the historic period can be attributed to factors including market accessibility and reimbursement, patient advocacy and awareness, physician education and training, biologic drug development and successful clinical trials.
What Does Future Hold for The Neutropenia Biologic Drug Treatment Market By 2029?
The neutropenia biologic drug treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for biologic drug treatment for neutropenia is anticipated to experience robust growth in the forthcoming years. By 2029, it's predicted to expand to a valuation of $18.1 billion, with a compound annual growth rate (CAGR) of 6.5%.
This projected growth during the forecast period is credited to factors such as healthcare cost management, the development of patient-focused care models, combined therapy advancements, regulatory revisions and approvals as well as personalized medicine strategies. Upcoming trends include increased global market access, enhancements in manufacturing methodologies, streamlined treatment protocols, the adoption of biosimilars, and the creation of long-lasting formulations.
What Are The Primary Growth Drivers In The Neutropenia Biologic Drug Treatment Market?
The increasing number of cancer cases worldwide is expected to fuel the demand for neutropenia biologic drugs in the market. The rise in cancer diagnoses and the higher percentage of people choosing chemotherapy has led to an uptick in neutropenia sufferers. For example, in January 2022, the American Cancer Society predicted that there would be 1.9 million new cancer cases and approximately 609,360 cancer-related deaths in the US, equating to nearly 1,670 deaths every day. The four most prevalent forms of cancer globally include lung, prostate, bowel and female breast cancer, constituting 43% of all new cancer diagnoses. As such, the global upsurge in cancer cases is foreseen to stimulate the demand in the neutropenia biologic drug treatment market in the upcoming years.
What Is The Segmentation Of The Global Neutropenia Biologic Drug Treatment Market?
The neutropenia biologic drug treatment market covered in this report is segmented –
1) By Drug Type: Filgrastim, Pegfilgrastim, Lenograstim, Lipegfilgrastim, Sargramostim
2) By Treatment Type: Antibiotic Drugs, Granulocyte-Colony-Stimulating Factor (G-CSF), Antifungal Drugs, Other Treatment Types
3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies
Subsegments:
1) By Filgrastim: Brand Name Examples: Neupogen, Indications And Usage
2) By Pegfilgrastim: Brand Name Examples: Neulasta, Indications And Usage
3) By Lenograstim: Brand Name Examples: Granocyte, Indications And Usage
4) By Lipegfilgrastim: Brand Name Examples: Lonquex, Indications And Usage
5) By Sargramostim: Brand Name Examples: Leukine, Indications And Usage
Pre-Book The Neutropenia Biologic Drug Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Neutropenia Biologic Drug Treatment Industry?
Significant pharmaceutical companies in the neutropenia biologic drug treatment sector are focusing on the creation of biosimilars as a more economical substitute to existing biologics. Biosimilars are essentially biologic drugs engineered to be almost identical to a pre-approved reference biologic, with no substantial differences in either safety or effectiveness. For instance, Amneal Pharmaceuticals, an American-based pharmaceutical firm, introduced Fylnetra (pegfilgrastim-pbbk), a biosimilar to Neulasta in May 2023. This product is targeted at treating and preventing febrile neutropenia in patients receiving chemotherapy. Fylnetra attaches to certain receptors on hematopoietic cells, promoting the expansion and differentiation of neutrophil precursors in the bone marrow. Consequently, this action elevates the production of neutrophils which are vital for warding off infections, especially in patients subjected to myelosuppressive chemotherapy. This aids in reducing the occurrence of febrile neutropenia related to cancer treatments.
Who Are the Key Players In The Neutropenia Biologic Drug Treatment Market?
Major companies operating in the neutropenia biologic drug treatment market include:
• Amgen Inc.
• Pfizer Inc.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• GlaxoSmithKline plc
• F. Hoffmann-La Roche Ltd
• Merck & Co. Inc.
• Johnson & Johnson
• Baxter International Inc.
• Mylan N.V.
• Celgene Corporation
• Biogen Inc.
• AbbVie Inc.
• Regeneron Pharmaceuticals Inc.
• AstraZeneca plc
• Eli Lilly and Company
• Takeda Pharmaceutical Company Limited
• Bayer AG
• Sun Pharmaceutical Industries Ltd.
• Lupin Limited
• Fresenius SE & Co. KGaA
• Gilead Sciences Inc.
• Daiichi Sankyo Company
• Kyowa Kirin Co. Ltd.
• CSL Limited
• Dr. Reddy's Laboratories Ltd.
• Bristol-Myers Squibb Company
• Astellas Pharma Inc.
• Otsuka Pharmaceutical Co. Ltd.
What Are The Regional Insights Into The Neutropenia Biologic Drug Treatment Market?
North America was the largest region in the neutropenia biologic drug treatment market in 2024. The regions covered in the neutropenia biologic drug treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
